Short-term outcomes of neonates with severe sepsis on intravenous colistin therapy – A prospective study

A high incidence of multidrug resistance (MDR) exists in many special neonatal care units, and ours is no exception<b>.</b> We therefore evaluated the short-term outcomes of 135 neonates with severe sepsis on intravenous colistimethate sodium (Colistin) therapy and its effect on the incidence of nephrotoxicity. We found 17.5% resistance with hardly any nephrotoxicity amongst 57 Gram-negative bacteria, suggesting colistin as a reasonable choice as a reserve drug, even in centres with high MDR incidence.